EClinical Trials of Targeted Alpha Therapy for Cancer
EClinical Trials of Targeted Alpha Therapy for Cancer
复制标题
DOI：
10.2174/157488708785700339
复制
发表时间：
2008-01-01
影响因子：
1.9
通讯作者：
Allen, Barry J.
中科院分区：
文献类型：
--
作者：
Allen, Barry J.
靶向α疗法是一种先进的实验性疗法，有望为靶向癌细胞提供高细胞毒性。最初被认为适用于白血病和微转移，现在有证据表明实体瘤也可以消退。α治疗可能是分子或生理靶向的。α发射放射性同位素如Bi-212、Bi-213、At-211和Ac-225用于标记靶向特定癌细胞的单克隆抗体或蛋白质。另外，镭-233也被用于乳腺癌和前列腺癌的姑息治疗，因为它是一种趋骨元素。阿尔法疗法的临床试验发展的进展被检查用于白血病，淋巴瘤，黑色素瘤，多形性胶质母细胞瘤，骨转移，卵巢癌，胰腺癌和其他癌症。回顾了过去和当前试验的结果，并提出了一些拟议试验的基础。
Targeted alpha therapy is an advancing experimental therapy that holds promise to deliver high cytotoxicity to targeted cancer cells. Initially thought to be indicated for leukaemia and micrometastases, there is now evidence that solid tumours can also be regressed.Alpha therapy may be molecular or physiological in its targeting. Alpha emitting radioisotopes such as Bi-212, Bi-213, At-211 and Ac-225 are used to label monoclonal antibodies or proteins that target specific cancer cells. Alternatively, radium-233 is used for palliative therapy of breast and prostate cancers as it is a bone seeking element.Progress in the development of clinical trials of alpha therapy is examined for leukaemia, lymphoma, melanoma, glioblastoma multiforme, bone metastases, ovarian cancer, pancreatic cancer and other cancers. Results of past and current trials are reviewed, and the bases of some proposed trials are presented.